Denali Therapeutics (DNLI) Cash & Equivalents (2017 - 2026)

Denali Therapeutics (DNLI) has 10 years of Cash & Equivalents data on file, last reported at $387.6 million in Q1 2026.

• Quarterly Cash & Equivalents rose 580.68% year-over-year to $387.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $387.6 million (up 580.68% YoY) and the FY2025 annual result came in at $205.3 million, up 17.36% from the prior year.
• Cash & Equivalents advanced to $387.6 million in Q1 2026 per DNLI's latest filing, from $205.3 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $387.6 million in Q1 2026 and bottomed at $56.9 million in Q1 2025.
• The 5-year median for Cash & Equivalents is $127.1 million (2023), against an average of $138.5 million.
• The widest annual swing landed in 2022, when Cash & Equivalents slumped 75.89%; it then surged 580.68% in 2026.
• Tracing DNLI's Cash & Equivalents over 5 years: stood at $218.0 million in 2022, then sank by 41.71% to $127.1 million in 2023, then surged by 37.65% to $175.0 million in 2024, then advanced by 17.36% to $205.3 million in 2025, then jumped by 88.79% to $387.6 million in 2026.
• Per Business Quant, the three latest DNLI Cash & Equivalents figures stand at $387.6 million (Q1 2026), $205.3 million (Q4 2025), and $91.0 million (Q3 2025).

Peer Comparison